Researcher.Life Logo

Journal of Autoimmunity : Impact Factor & More

eISSN: 1095-9157pISSN: 0896-8411

Aims and Scope of Journal of Autoimmunity

The Journal of Autoimmunity is a peer-reviewed medical journal covering research on all aspects of autoimmunity. It was established in 1988 and is published 8 times per year by Elsevier. The editors-in-chief are Yehuda Shoenfeld (Sheba Medical Center) and M. Eric Gershwin (University of California, Davis). According to the Journal Citation Reports, the journal has a 2016 impact factor of 7.641. Less

Key Metrics

CiteScore
19.9
Eigenfactor
0.01 - 0.05
Impact Factor
10 - 15
SJR
Q1Immunology
SNIP
2.92
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Journal of Autoimmunity

Journal of Autoimmunity Journal Specifications

Overview
Publisher ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1988
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Journal of Autoimmunity ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Journal of Autoimmunity

Targeting autoreactive B cells in rheumatoid arthritis through MHC class I-presented BCR-derived neo-epitopes.
  • 30 Jun 2026
  • Journal of autoimmunity
Efficacy, safety, and tolerability of treatments for interstitial lung disease associated with rtoid arthritis: A systematic review and network meta-analysis.
  • 20 Jun 2026
  • Journal of autoimmunity
Celiac disease plasma cells recognize the active form of transglutaminase 2 with and without bound substrate.
  • 18 Jun 2026
  • Journal of autoimmunity
Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition.
  • 17 Jun 2026
  • Journal of autoimmunity
Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance.
  • 11 Jun 2026
  • Journal of autoimmunity
Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study.
  • 1 Jun 2026
  • Journal of autoimmunity
Targeting autoreactive B cells in rheumatoid arthritis through MHC class I-presented BCR-derived neo-epitopes.
  • 30 Jun 2026
  • Journal of autoimmunity
Efficacy, safety, and tolerability of treatments for interstitial lung disease associated with rtoid arthritis: A systematic review and network meta-analysis.
  • 20 Jun 2026
  • Journal of autoimmunity
Celiac disease plasma cells recognize the active form of transglutaminase 2 with and without bound substrate.
  • 18 Jun 2026
  • Journal of autoimmunity
Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition.
  • 17 Jun 2026
  • Journal of autoimmunity
Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance.
  • 11 Jun 2026
  • Journal of autoimmunity
Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study.
  • 1 Jun 2026
  • Journal of autoimmunity

FAQs on Journal of Autoimmunity